Singapore, June 22 -- Insilico Medicine, a Hong Kong-based clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and South Korea-based SK Biopharmaceuticals, have announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system (CNS).

Neuroimmune disorders, including neuroinflammatory, neurodegenerative, and rare neurological disorders, remain among the most challenging therapeutic areas in modern medicine, with significant unmet patient need and historically low clinical success rates.

Under the agreement, Insilico will leverage its proprietary Pharma.AI platform, which spans...